help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on February 26, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-2492
A more recent version of this article appeared on May 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/5/1789    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Samelson, E. J.
Right arrow Articles by Kiel, D. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samelson, E. J.
Right arrow Articles by Kiel, D. P.
Related Collections
Right arrow Calcium and Bone Metabolism

Submitted on November 9, 2007
Accepted on February 20, 2008

Increased Plasma Osteoprotegerin Concentrations are Associated with Indices of Bone Strength of the Hip

Elizabeth J. Samelson*, Kerry E. Broe, Serkalem Demissie, Thomas J. Beck, David Karasik, Sekar Kathiresan, and Douglas P. Kiel

Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA; Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MA, USA; Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

* To whom correspondence should be addressed. E-mail: samelson{at}hrca.harvard.edu.

Objective: Osteoprotegerin (OPG) is an important regulator of bone turnover through its effects on osteoclastogenesis, yet findings from previous studies of circulating OPG and commonly measured bone indices in humans have been conflicting. We conducted a cross-sectional study to evaluate the association between plasma OPG and femoral neck bone density (FN BMD) and geometry in a large cohort of women and men.

Design: Participants included 1379 post-menopausal women and 1165 men, age 50–89 years (mean, 64 years), in the Framingham Offspring Study. Dual x-ray absorptiometry was used to evaluate FN BMD and geometry (bone width, section modulus, and cross-sectional area at the narrow neck region). Plasma OPG concentrations were measured by ELISA. Sex-specific analysis of covariance was used to calculate means and assess linear trend in BMD and geometry values across OPG quartiles, adjusted for confounders.

Results: OPG concentrations were greater in women than men, increased with age, and were greater in smokers and those with diabetes and heart disease. Multivariable-adjusted mean FN BMD in women increased from the lowest to the highest OPG quartile (trend, p<0.01). However, no linear trend between FN BMD and OPG was observed in men (trend, p=0.34). Section modulus and bone width increased with OPG in men (trend, p<0.01), whereas no association between hip geometry indices and OPG was observed in women.

Conclusion: Higher OPG concentration may indicate greater skeletal strength in women and men, possibly through reducing bone loss in women and through increasing periosteal apposition in men.


Key words: osteoprotegerin • bone density • hip geometry







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society